KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Return on Invested Capital (2018 - 2026)

Alnylam Pharmaceuticals filings provide 11 years of Return on Invested Capital readings, the most recent being 0.01% for Q1 2026.

  • On a quarterly basis, Return on Invested Capital rose 1.0% to 0.01% in Q1 2026 year-over-year; TTM through Mar 2026 was 0.01%, a 1.0% increase, with the full-year FY2025 number at 0.01%, down 3.0% from a year prior.
  • Return on Invested Capital hit 0.01% in Q1 2026 for Alnylam Pharmaceuticals, down from 0.01% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.07% in Q4 2022 to a low of 0.13% in Q3 2024.
  • Median Return on Invested Capital over the past 5 years was 0.01% (2026), compared with a mean of 0.0%.
  • Biggest five-year swings in Return on Invested Capital: decreased -15bps in 2024 and later rose 15bps in 2025.
  • Alnylam Pharmaceuticals' Return on Invested Capital stood at 0.07% in 2022, then plummeted by -79bps to 0.01% in 2023, then plummeted by -191bps to 0.01% in 2024, then skyrocketed by 163bps to 0.01% in 2025, then fell by -7bps to 0.01% in 2026.
  • The last three reported values for Return on Invested Capital were 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.02% (Q3 2025) per Business Quant data.